U.S. Cell And Gene Therapy Clinical Trials Market Size & Outlook
U.S. cell and gene therapy clinical trials market, 2018-2030 (US$M)
Related Markets
U.S. cell and gene therapy clinical trials market highlights
- The U.S. cell and gene therapy clinical trials market generated a revenue of USD 4,102.3 million in 2023 and is expected to reach USD 10,955.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 15.1% from 2024 to 2030.
- In terms of segment, phase ii was the largest revenue generating phase in 2023.
- Phase II is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy clinical trials market data book summary
| Market revenue in 2023 | USD 4,102.3 million |
| Market revenue in 2030 | USD 10,955.8 million |
| Growth rate | 15.1% (CAGR from 2023 to 2030) |
| Largest segment | Phase ii |
| Fastest growing segment | Phase II |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
Other key industry trends
- In terms of revenue, U.S. accounted for 43.9% of the global cell and gene therapy clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 10,955.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Clinical Trials Market Scope
Cell And Gene Therapy Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cell and gene therapy clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 55.45% in 2023. Horizon Databook has segmented the U.S. cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
U.S. was the largest market in the North American region and contributed to more than 90% of the market share in 2021. This is attributed to the increasing number of cell and gene therapy clinical trials being performed in the U.S. As per the PhRMA, there are 4,516 cell and gene therapy clinical trials in the U.S. with 9, 20,172 participants and USD 15.2 billion investments at clinical trial sites.
Also, 362 investigational cell and gene therapies currently in clinical development – a 20% increase since 2018 for treating cancer, eye diseases and rare hereditary diseases. Besides, biopharmaceutical industry in the U.S. has been the world leader in the development of new medicines. In 2018, the biopharmaceutical industry invested around USD 102 billion in R&D. Besides, the presence of well-established contract research organizations in the U.S. is boosting the market growth.
Instances include IQVIA; ICON plc; Parexel International Corporation; Syneos Health, Inc.; Charles River Laboratory to name a few. The market players are also adopting strategies to remain competitive in the market with the introduction of the new product to ease the conduct of Cell and Gene Therapy Clinical Trials, geographic expansion, the addition of new services in the portfolio, and collaboration.
Reasons to subscribe to U.S. cell and gene therapy clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cell and gene therapy clinical trials market databook
-
Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)
U.S. Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
